SBC Medical | 10-Q: FY2025 Q3 Revenue: USD 43.35 M

Revenue: As of FY2025 Q3, the actual value is USD 43.35 M.

EPS: As of FY2025 Q3, the actual value is USD 0.12.

EBIT: As of FY2025 Q3, the actual value is USD 15.81 M.

Segment Revenue

• Franchising Revenue: $35,656,250 for the nine months ended September 30, 2025, a decrease of $9,768,802 or 21.51% from $45,425,052 for the same period in 2024.
• Procurement Revenue: $43,496,207 for the nine months ended September 30, 2025, a decrease of $807,684 or 1.82% from $44,303,891 for the same period in 2024.
• Management Services Revenue: $23,328,864 for the nine months ended September 30, 2025, a decrease of $21,142,167 or 47.54% from $44,471,031 for the same period in 2024.
• Rental Services Revenue: $18,711,335 for the nine months ended September 30, 2025, an increase of $7,515,447 or 67.13% from $11,195,888 for the same period in 2024.
• Other Revenue: $12,848,127 for the nine months ended September 30, 2025, a decrease of $2,751,016 or 17.64% from $15,599,143 for the same period in 2024.

Operational Metrics

• Net Income: $36,765,128 for the nine months ended September 30, 2025, a decrease of $3,376,880 or 8.41% from $40,142,008 for the same period in 2024.
• Gross Profit: $98,355,148 for the nine months ended September 30, 2025, a decrease of $23,822,992 or 19.50% from $122,178,140 for the same period in 2024.
• Operating Expenses: $43,717,642 for the nine months ended September 30, 2025, a decrease of $12,874,450 or 22.75% from $56,592,092 for the same period in 2024.

Cash Flow

• Net Cash Used in Operating Activities: -$27,295,426 for the nine months ended September 30, 2025, compared to $27,886,231 provided by operating activities for the same period in 2024.
• Net Cash Provided by Investing Activities: $3,239,523 for the nine months ended September 30, 2025, compared to -$5,554,039 used in investing activities for the same period in 2024.
• Net Cash Provided by Financing Activities: $18,470,001 for the nine months ended September 30, 2025, compared to $11,584,038 for the same period in 2024.

Future Outlook and Strategy

• Core Business Focus: The company plans to maintain and strengthen its market position and brand in the cosmetic medical treatment management market in Japan, Vietnam, and Singapore, and grow its presence globally.
• Non-Core Business: The company is proceeding with the acquisition of common shares of Waqoo, Inc., a Japanese company listed on the Tokyo Stock Exchange, to obtain controlling interest and integrate its advanced technologies and expertise within the SBC Group.